Welcome to our dedicated page for Claritev SEC filings (Ticker: CTEV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Claritev Corporation (NYSE: CTEV) files a range of documents with the U.S. Securities and Exchange Commission that detail its operations as a healthcare technology, data and insights company. As an issuer of Class A common stock listed on the New York Stock Exchange, Claritev provides investors with periodic and current reports that describe its financial performance, capital structure, client relationships and key corporate events.
On this page, you can access Claritev’s SEC filings, including current reports on Form 8-K that the company uses to announce material developments. Recent 8-K filings have covered topics such as quarterly financial results, contract renewals with its ten largest clients, underwriting agreements for secondary offerings of Class A common stock by selling stockholders, and changes in executive roles. These filings also confirm that Claritev’s Class A common stock, with a par value of $0.0001 per share, is registered under Section 12(b) and trades under the symbol CTEV on the NYSE.
Claritev’s earnings-related filings and exhibits provide detail on revenues, net income or loss, and non-GAAP metrics such as EBITDA, Adjusted EBITDA, Free Cash Flow, Unlevered Free Cash Flow and an Adjusted cash conversion ratio. The company defines these measures and explains their limitations, giving investors insight into how management evaluates performance and cash generation alongside GAAP results.
Through Stock Titan, these filings are complemented by AI-powered summaries that help explain the significance of each document. Investors can quickly see the key points from Claritev’s 8-Ks, and, where available, review annual reports on Form 10-K, quarterly reports on Form 10-Q, proxy materials and other disclosures. This page also provides a pathway to monitor any insider-related filings, such as Form 4 reports, that may be associated with Claritev’s equity compensation and ownership changes, offering a structured view of the company’s regulatory reporting history.
Claritev Corp EVP and COO Jerome Hogge reported equity award and related tax dispositions. On March 1, 2026, he received 66,322 shares of Class A common stock as a grant. The filing also shows share dispositions tied to tax withholding and the cash settlement of previously granted cash-settled RSUs.
Claritev Corp senior vice president and chief strategy officer William B. Mintz reported equity compensation activity tied to restricted stock units. On March 1, 2026, he disposed of 6,431 cash-settled RSUs back to the company upon vesting of half of a 2025 cRSU grant, leaving 6,432 cash-settled RSUs outstanding. On the same date, 1,137 Class A common shares at $13.47 per share were withheld to cover taxes on vesting of earlier RSUs. He also received a new grant of 19,060 restricted stock units, scheduled to vest in four equal annual installments of 25% each on March 1, 2027, 2028, 2029, and 2030. Following these transactions, Mintz directly held 83,248 shares of Class A common stock.
Claritev Corp reported that SVP and Chief Accounting Officer Albinson Brock acquired an equity award tied to 23,243 shares of Class A common stock as a grant of restricted stock units. These RSUs vest 25% each on March 1 of 2027, 2028, 2029 and 2030. Following this grant, Brock beneficially owns 27,237 shares directly.
Claritev Corp SVP and Chief Growth Officer Tiffani Misencik reported a mix of equity award activity and related share dispositions. She received a grant of 26,342 restricted stock units, which will vest 25% each year on March 1 of 2027, 2028, 2029, and 2030.
On the same date, 10,123 cash-settled restricted stock units granted in 2025 were settled in cash following the vesting of 50% of that award. In addition, 1,660 shares of Class A common stock at $13.47 per share were withheld to cover taxes on vesting, leaving her with 132,573 Class A shares directly owned.
Claritev Corp executive Carol Nutter, SVP and Chief People Officer, reported multiple equity transactions. She received a grant of 18,130 shares of Class A common stock as restricted stock units, which will vest 25% each on March 1 of 2027, 2028, 2029 and 2030.
On the same date, Nutter disposed of 1,229, 498 and 1,085 Class A shares at $13.47 per share to cover taxes on vesting RSUs originally granted in 2023, 2024 and 2025. She also disposed of 6,127 cash-settled restricted stock units through a cash settlement tied to 50% vesting of a prior cRSU grant. After these transactions, she directly owns 46,066 Class A shares.
Claritev Corp director and CEO Dalton Travis reported a mix of equity award activity and related share disposals on March 1, 2026. He received a grant of 278,925 shares of Class A common stock as a restricted stock unit award, recorded as a grant or other acquisition. To cover tax obligations from vesting of earlier restricted stock units granted on March 1, 2024 and March 1, 2025, 13,806 and 9,824 Class A shares, respectively, were disposed of through tax-withholding transactions at a price of $13.47 per share. In addition, 190,566 cash settled restricted stock units granted on March 1, 2025 were settled in cash upon vesting of 50% of those units, reducing his position in that derivative security. After these transactions, he directly held 498,353 Class A shares and 190,567 cash settled restricted stock units, and there were 24,952 Class A shares held indirectly through his spouse’s individual retirement account.
Claritev Corp executive vice president and chief digital officer Kim Michael reported an open-market purchase of 30,000 shares of Class A common stock on February 27, 2026 at a weighted average price of $14.2985 per share. Following this transaction, Michael directly owns 137,973 shares.
Claritev Corp director and Pres., CEO & Executive Chair Dalton Travis reported an open-market purchase of 15,380 shares of Class A common stock on February 27, 2026. The shares were bought indirectly through his spouse's individual retirement account at a weighted average price of $12.9992 per share. After these transactions, he reported 24,952 shares held indirectly through the spouse’s IRA and 243,058 shares held directly.
Claritev Corp senior vice president and general counsel Tara O'Neil reported an open-market purchase of 750 shares of Class A common stock at a price of $12.99 per share. Following this transaction, her directly held stake increased to 27,199 shares.
Claritev Corporation describes itself as a technology, data and insights company focused on reducing cost, risk and complexity in the U.S. healthcare system. The company serves more than 750 payer clients and estimates its solutions touch over 60 million consumers through 100,000+ plan sponsors.
Claritev reports identifying $25.0 billion in potential savings on $179.8 billion in claim charges in 2025, leveraging a platform that processes about 30 million claims per month and a proprietary network of over 1.4 million contracted providers. It estimates total addressable markets of roughly $10.0 billion for out-of-network cost management, $3.0 billion for in‑network payment and revenue integrity, and $17.0 billion for newer analytics and transparency offerings.
The report outlines the Vision 2030 strategy and notes 2025 was branded “THE TURN,” marking a return to year‑over‑year revenue growth, with 2026 branded “THE WAY UP.” Key risks include dependence on a few large clients, high leverage, intense competition, extensive healthcare regulation and cybersecurity and data‑privacy exposure. As of June 30 2025, non‑affiliate market value was about $505.8 million, and as of February 23 2026, 16,552,723 Class A shares were outstanding.